enow.com Web Search

  1. Ad

    related to: castration resistant cancer prognosis symptoms in men over 60

Search results

  1. Results from the WOW.Com Content Network
  2. Prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer

    Prostate cancer is the most diagnosed cancer in men in over half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. [91] Prostate cancer is rare in those under 40 years old, [92] and most cases occur in those over 60 years, [2] with the average person diagnosed at 67. [93]

  3. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [ 28 ]

  4. DU145 - Wikipedia

    en.wikipedia.org/wiki/DU145

    Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).

  5. Medical uses of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

    Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

  6. Androgen deprivation therapy - Wikipedia

    en.wikipedia.org/wiki/Androgen_deprivation_therapy

    Cancer Stem Cell phenotypes are associated with disease recurrence, metastasis, and cell survival in circulation as Circulating tumor cells. Thus, activation of these programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.

  7. Cancer rates in men will increase by a whopping 84% over the ...

    www.aol.com/news/cancer-rates-men-increase...

    Cancer rates in men are projected to jump by 84 percent from 2022 to 2050, while cancer deaths are expected to increase by 93.2 percent over the same time frame, according to the peer-reviewed study.

  8. Darolutamide - Wikipedia

    en.wikipedia.org/wiki/Darolutamide

    Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4]

  9. The reality of breast cancer in men - AOL

    www.aol.com/reality-breast-cancer-men-150047070.html

    The five-year survival rate for men with breast cancer is about 77.6%, compared with 86.4% in women, partly due to later diagnoses. However, the treatments — surgery, radiation, chemotherapy ...

  1. Ad

    related to: castration resistant cancer prognosis symptoms in men over 60